Metformin and blood pressure
Pro Research Analysisby 
Searched over 200M research papers
Metformin and Blood Pressure: Effects in Diabetic and Nondiabetic Populations
Blood Pressure Reduction in Nondiabetic and Obese Individuals
Multiple studies show that metformin can lower systolic blood pressure (SBP) in nondiabetic patients, especially those with impaired glucose tolerance or obesity. A large meta-analysis found that metformin reduced SBP by about 2 mmHg overall, with greater reductions (up to 5 mmHg) in people with obesity or impaired glucose tolerance. However, the effect on diastolic blood pressure (DBP) was not significant in these groups . Similar findings were observed in pilot studies and clinical trials, where metformin improved insulin sensitivity and led to marked decreases in blood pressure among non-obese, non-diabetic hypertensive individuals Landin-Wilhelmsen1992Giugliano1993.
Blood Pressure Effects in Type 2 Diabetes
In patients with type 2 diabetes, the effect of metformin on blood pressure appears to be small and often not statistically significant. A systematic review of randomized controlled trials found that metformin did not have a significant intrinsic effect on either SBP or DBP in this population, although it did improve lipid profiles . However, some studies suggest that metformin can attenuate the postprandial fall in blood pressure (postprandial hypotension), a common issue in type 2 diabetes, by slowing gastric emptying and increasing GLP-1 secretion Borg2019Quast2025.
Mechanisms of Blood Pressure Reduction
The blood pressure-lowering effects of metformin are likely indirect. Metformin improves insulin sensitivity, reduces plasma insulin, and has beneficial effects on cholesterol and triglycerides, which may contribute to lower blood pressure Landin-Wilhelmsen1992Bakhshaei2022Giugliano1993. Other proposed mechanisms include nephroprotective and cardioprotective effects, improvement of endothelial function, and modulation of the sympathetic nervous system . Genetic studies also suggest that metformin’s action on specific targets (such as mitochondrial complex I and MG3) may play a key role in reducing both SBP and DBP, as well as the overall risk of hypertension .
Metformin in Combination with Antihypertensive Therapy
Adding metformin to standard antihypertensive therapy (such as lisinopril) in hypertensive patients with prediabetes has been shown to further decrease both mean blood pressure and blood pressure variability, particularly in the morning, compared to antihypertensive therapy alone .
Limitations and Organ Protection
While metformin can lower blood pressure, animal studies indicate that this does not always translate into reduced organ damage from hypertension. For example, in a rat model of severe hypertension, metformin lowered blood pressure but did not prevent heart or kidney damage .
Postprandial Blood Pressure Regulation
Metformin has been shown to reduce the frequency and severity of postprandial hypotension in people with type 2 diabetes, likely through effects on gastric emptying and GLP-1 secretion, without affecting pre-meal blood pressure Borg2019Quast2025.
Conclusion
Metformin can modestly lower systolic blood pressure, especially in nondiabetic, obese, or insulin-resistant individuals, and may help reduce postprandial hypotension in type 2 diabetes. Its blood pressure-lowering effects are mainly indirect, related to improved insulin sensitivity and metabolic health. However, in people with established type 2 diabetes, the effect on blood pressure is generally small. Metformin’s benefits on cardiovascular risk likely extend beyond blood pressure control, involving improvements in lipid profiles and vascular function.
Sources and full results
Most relevant research papers on this topic